CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups
Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.
Related Articles
Obe-Cel Receives Positive CHMP Opinion for R/R B-Cell ALL
The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.
2025 ASCO Annual Meeting: The Show and After Show
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends…
How blood and bone marrow transplant expertise is changing cancer care at Ohio State
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
Panelists discuss how amivantamab plus lazertinib therapy for EGFR-mutant non–small cell lung cancer has shown promising survival data while highlighting the importance of managing adverse…
Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
Kit Yu Lu, MD, discussed the implications of the TROPiCS-02 and DESTINY-Breast06 trial data for sequencing ADCs in HR+/HER2– breast cancer.
Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
Currently, sacituzumab govitecan, T-DXd, and Dato-DXd cannot be compared in HR+/HER2– breast cancer due to a lack of head-to-head trials.
What you need to know about gynecologic cancer, including symptoms, screening and treatment
Through care, research and prevention practices, doctors are working with gynecologic cancer patients to reduce cases and save lives through early detection.
Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC
Given an unmet need for efficacious therapies against ALK-positive NSCLC, experts discuss optimal ALK TKI sequencing for patients with this disease.
China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL
Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer
“The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working,” stated Monica Khunger Malhotra, MD.